Euflexxa denied? Start your appeal.
Start with the reason on your denial notice. Check your plan’s appeal route, then gather the records that answer the specific coverage rule.
No account or payment to check your route. You confirm the plan facts; published review outcomes do not predict your result.
Free evidence checklist for knee osteoarthritis
What to gather for a knee injection appeal
Use the published decisions to ask better questions, then answer the exact rule in your denial. Bring this checklist to your treating clinician; it does not tell you which treatment to choose.
Download blank checklist (.txt)- The denial and the applicable rule. Keep the complete notice, notice date, filing deadline, recipient, and the exact plan policy or criterion cited. Ask which benefit covers the injection and whether the dispute is medical necessity, a preferred product, repeat timing, or a billing issue.
- Diagnosis, knee, and functional limits. Ask the clinician to identify the affected knee, diagnosis, relevant imaging report, and how pain limits walking, standing, or other daily activities. Do not infer a diagnosis from pain alone.
- Conservative care already tried. List each treatment, dates, duration, response, and adverse effects. Include non-drug approaches and medicines where relevant. Ask the clinician to explain any contraindication instead of treating a contraindicated therapy as a required trial.
- Why this product and this request. Ask the prescriber to answer the actual denial criterion, explain the individual rationale, and check the requested dose and schedule against current product labeling. Approval of one hyaluronic-acid product does not establish coverage for every product.
- If this is a repeat series. Record prior injection dates, which knee was treated, measurable pain and function changes, when symptoms returned, and why the timing satisfies the applicable policy. A first series and a repeat series can have different criteria.
- A complete submission record. Match each disputed criterion to an attachment. Confirm the governing appeal route, send it using the notice instructions, and keep the submission receipt. Ask the clinician about an urgent review if waiting could seriously harm health.
Coverage criteria and clinical guidance are different
For example, Medicare LCD L39260 requires documented symptomatic knee osteoarthritis, radiographic support, a qualifying conservative-care history, and other criteria. Repeat treatment has separate requirements, including a prior response and a minimum interval. This is a local policy: verify the contractor, service date, and complete rule before relying on it.
AAOS does not recommend hyaluronic-acid injections for routine knee osteoarthritis use. Favorable historical reviews do not erase that limitation. Ask the clinician to explain the individual rationale and address the plan's criteria. For Monovisc, consult the FDA approval record and current labeling; FDA approval is not a coverage guarantee.
U.S. self-help preparation for knee osteoarthritis injection denials; not medical or legal advice. The historical California review rate is not your chance of success. L39260 is a local Medicare policy, not a nationwide rule for every plan. Confirm contractor jurisdiction, service date, and the policy in your notice. Clinical guidance and FDA labeling do not guarantee insurance coverage. Sources reviewed 2026-09-05.
- FDA: Monovisc approval record and labeling
- CMS: local coverage determination L39260
- AAOS: knee osteoarthritis clinical guideline
The download is a blank, printable worksheet. Fill it in privately; nothing you write in the downloaded file is sent to Coverage Rights.
In the California DMHC record, independent physician reviewers decided 35 published external-review cases involving Euflexxa and overturned the plan’s denial in 65.7%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Osteoarthritis Of The Knee | 15 | 80% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 28 | 75% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 7 | 28.6% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: A 62-year-old female enrollee has requested authorization and coverage for Euflexxa shots series of three for the left knee every six months. In the current peer-reviewed medical literature, the authors conducted a systematic review on the efficacy and safety of repeat courses of hyaluronan therapy in patients with osteoarthritis of the knee. The authors concluded that repeat courses of the hyaluronans were safe and effective in the treatment of pain associated with osteoarthritis of the knee. Further, the researchers found that repeated cycles of intra-articular sodium hyaluronate in patients with knee osteoarthritis was found efficacious during a 54-month follow-up period.
Nature of Statutory Criteria/Case Summary: An enrollee has requested Euflexxa injections for treatment of the enrollee’s osteoarthritis. Findings: The physician reviewer found that the evidence based medical peer-reviewed literature supports the use of repeat series of viscosupplementation injections for the treatment of pain in patients with osteoarthritis of the knee. Bannuru and colleagues concluded that hyaluronic acid was the best pharmacologic intervention for knee osteoarthritis in their meta-analysis of 137 studies with 33,243 participants. Hyaluronic acid was found to be better than injected placebo or injected corticosteroids.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested Euflexxa injections for treatment of her osteoarthritis. Findings: The physician reviewer found that the evidence based medical guidelines and peer-reviewed literature does not support the use of hyaluronic acid injections, such as Euflexxa, for osteoarthritis in the knees. Its use for treatment of osteoarthritis of the knee remains the subject of debate because the use of hyaluronan is not consistently supported by evidence based literature. The rationale for the use of hyaluronan includes the concept that proinflammatory mediators and metalloproteinases (MMPs) that stimulate chondrocytes to syntheses endogenous hyaluronic acid and proteoglycans will be affected positively by the injection of hyaluronic acid.
Nature of Statutory Criteria/Case Summary: An enrollee has requested Euflexxa injections for treatment of his medical condition. Findings: The physician reviewer found that evidence based peer-reviewed literature and clinical practice guidelines have indicated that intraarticular steroid injections are a first line pharmacological intervention consideration in the treatment of knee arthritis, while intraarticular hyaluronan injections like Euflexxa are a second line consideration (Cheng, et al; 2012; Henrotin, et al; and Hochberg, et al). Jevsevar and colleagues performed a systematic review of the published evidence and concluded that, “Meta-analysis of only the double-blinded, sham-controlled trials with at least sixty patients did not show clinically important differences of HA treatment over placebo.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Euflexxa, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY